1Shiger U, Osamu M. Development of New Fibrinolytie Agents [J].Current Pharmaceutieat Design, 2006,12 : 849-857.
2Ueshima S, Matsuno H, Hayashi M,et al. Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombosis in vivo[J]. Thromb Haemost, 2002,87 : 1069-1074;
3Folkes A. Roe MB,Sohal S,et al. Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1[J]. Bioorg Med Chem Lett,2001,11(19):2589.
6Yu YS, Zhou YR, Lu JS,et al. The construction and characterization of human pro-urokinase mutant [J].Sheng Wu Gong Cheng Xue Bao. 2005 ; 21(4) : 573-581.
8Irina Y, Rachel A, Aiilyan K,et al. The fibrin-specific streptokinase SKΔ59 is a potent fibrinolytic agent in vivo[J]. American Heart Association, 2006 114 : 11-30.
9Chen Hongshan, Mo Wei, Zhang Yanling, et al. Functional properties of a novel mutant of staphylokinase with platelet-targeted fibrinolysis and antiplatelet aggregation activities[J]. European Journal of Phyarmacology,2007,566:137-144.
10Chen H, Mo W, Su H,et al. Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activities[J].BMC Mol Biol,2007,8:88.
